HLX02, a China-manufactured trastuzumab biosimilar versus EU-sourced trastuzumab: Results of a global phase 3, randomized, double-blind efficacy and safety comparative study in metastatic breast cancer. (October 2020) - Xu, B.; Zhang, Q.; Sun, T.; Li, W.; Teng, Y.; Hu, X.; Bondarenko, I.; Adamchuk, H.; Li, Y.; Shan, B.; Cheng, J.; Wang, X.; et al.